European journal of hospital pharmacy : science and practice最新文献

{"title":"Study of therapeutic patient education practices in French renal transplantation centres.","authors":"Camille Boissiere, Tristan Rallon, Cécile Vigneau, Elouan Demay, Claire Chatron, Astrid Bacle","doi":"10.1136/ejhpharm-2023-004006","DOIUrl":"10.1136/ejhpharm-2023-004006","url":null,"abstract":"<p><strong>Objectives: </strong>Therapeutic patient education (TPE) plays a critical role in the management of kidney transplant recipients. However, discrepancies exist in the guidance provided regarding the usage of immunosuppressants across different kidney transplant centres in France.</p><p><strong>Methods: </strong>To assess the current landscape of TPE practices in this patient population, an online questionnaire consisting of 51 questions was distributed to 32 French renal transplantation centres.</p><p><strong>Results: </strong>The participation rate in our survey was 96.9%, (31 of the 32 centres contacted). The respondents had diverse professions: they were nurses (15/31), physicians (9/31) and pharmacists (7/31). Virtually all institutions have implemented TPE initiatives, with an implementation rate of 93.5% (29/31). The topic of anti-rejection medication was consistently addressed, with only one centre not providing support at the conclusion of these sessions. However, the content of the sessions varied significantly from one centre to another, particularly regarding the proper management of anti-rejection medications. Only 19.4% (6/31) of the centres provided the correct recommendation regarding fasting when taking tacrolimus. Dietary guidance was a topic covered in 89.7% (26/29) of the centres, but significant divergences were also observed. TPE teams primarily consisted of nurses, with pharmacists present in only 51.6% (16/31) of the centres. We also observed limited involvement of patient partners, with just 9.7% (3/31) of the centres including them in their programme.</p><p><strong>Conclusion: </strong>These findings highlight considerable variability in the approach towards TPE among kidney transplant centres. Addressing counselling variability and increasing pharmacist and patient partner involvement is an essential step to improving the quality and effectiveness of TPE. By establishing a standardised and comprehensive approach to patient education, healthcare providers can ensure that kidney transplant recipients receive information that will ultimately help them improve their health and well-being.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"444-449"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140012515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutropenia possibly caused by cefoperazone/sulbactam.","authors":"Yun Li, Xiao Fang He, Ran Wang","doi":"10.1136/ejhpharm-2024-004188","DOIUrl":"10.1136/ejhpharm-2024-004188","url":null,"abstract":"<p><p>Neutropenia is a rare complication of drug therapy and is usually underdiagnosed. Cefoperazone/sulbactam is a combination of broad-spectrum antibacterial agents. Data on cefoperazone/sulbactam-induced neutropenia are limited. Herein, we report the case of a 35 year-old female patient who was admitted to the hospital due to an appendiceal abscess. After anti-infective treatment with cefoperazone/sulbactam, the patient developed neutropenia on day 4. After discontinuing treatment with cefoperazone/sulbactam, the patient's white blood cells and neutrophils gradually returned to normal. Hence, clinicians should monitor changes in neutrophil count during cefoperazone/sulbactam therapy and provide timely treatment.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"485-487"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond conventional dosing: tailoring antimicrobial regimens for cachexia.","authors":"Emine Ecem Kilinc, Izgi Bayraktar, Emre Kara, Kutay Demirkan, Murat Akova","doi":"10.1136/ejhpharm-2024-004250","DOIUrl":"10.1136/ejhpharm-2024-004250","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"491-492"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physicochemical stability of pevonedistat at 50, 100 and 200 µg/mL diluted in 0.9% sodium chloride and at 10 mg/mL in partially used vials.","authors":"Ralitsa Doncheva, Elise D'Huart, Nathalie Sobalak, Jean Vigneron, Béatrice Demoré","doi":"10.1136/ejhpharm-2023-003884","DOIUrl":"10.1136/ejhpharm-2023-003884","url":null,"abstract":"<p><strong>Objectives: </strong>Pevonedistat is a new cytotoxic used in association with azacitidine for the treatment of acute myeloid leukaemia and high-risk myelodysplastic syndromes. The manufacturer indicates an 18-hour stability after dilution in dextrose 5% or 0.9% sodium chloride (0.9% NaCl) at 2-8°C. No information is given for re-using vials of pevonedistat.Our objectives were to study the physico-chemical stability of 50 and 200 µg/mL pevonedistat diluted in 0.9% NaCl, in glass tubes, 100 µg/mL in 0.9% NaCl in polyolefin infusion bags, and 10 mg/mL partially used vials with a Spike. All preparations were stored at 2-8°C, protected from light.</p><p><strong>Materials and methods: </strong>Due to the limited quantity of pevonedistat available for this study, we prepared test solutions at 50 and 200 µg/mL in glass tubes in a small volume of 20 mL. Inorder to verify the absence of a sorption phenomenon of the molecule onto polyolefin, we prepared two infusion bags at 100 µg/mL. We tested concentrated solution at 10 mg/mL. At each analysis time, we tested three samples of each condition by high performance liquid chromatography (HPLC) coupled with a photodiode array detector. Physical stability was evaluated by a visual and sub-visual inspection. We measured pH at each analysis time.</p><p><strong>Results: </strong>Diluted solutions at 50 and 200 µg/mL in tubes and at 100 mg/mL in infusion bags retained more than 95% of the initial concentration for 14 days, the concentrated solution at 10 mg/mL did so for 7 days. No physical changes were detected visually or sub-visually. We found that pH values remained stable.</p><p><strong>Conclusion: </strong>All diluted solutions remained physically and chemically stable for 14 days, the concentrated solution did so for 7 days. No interactions between the polyolefin bag and pevonedistat were demonstrated. This new data allows re-using the concentrated solution of pevonedistat in a commercial glass vial with a Spike, and storing a preparation in case of non-administration.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"479-484"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The frequency and impact of drug-related problems with postoperative medication reported by orthopaedic patients after discharge.","authors":"Eward J Melis, Bart Jf van den Bemt, Dirk E Schrander, Johanna E Vriezekolk","doi":"10.1136/ejhpharm-2024-004328","DOIUrl":"10.1136/ejhpharm-2024-004328","url":null,"abstract":"<p><p>Following orthopaedic surgery, medication is vital for recovery and preventing complications, however drug-related problems (DRPs) can hinder medication use. The prevalence, types, and impact of DRPs on patients' activities of daily living (ADL) and the medication involved are unknown. Insight is needed for targeted interventions.</p><p><strong>Aim: </strong>Our study had four aims to assess 1) the prevalence and types of DRPs with postoperative medication in orthopeadic patients 6 weeks after discharge; 2) the perceived impact of the reported DRPs on patients' ADL; 3) the postoperative medication most frequently causing DRPs; and 4) the association between DRP numbers and patient- and disease-related characteristics.</p><p><strong>Methods: </strong>A cross-sectional study at a tertiary centre surveyed adult orthopaedic surgery patients 6 weeks post-surgery. Patients reported on demographics, DRPs and their ADL impact, health literacy, and medication beliefs. Clinical factors and medication use were extracted from medical records. Descriptive statistics and linear hierarchical regression analysis were conducted.</p><p><strong>Results: </strong>Out of 484 patients (mean (standard deviation (SD)) age 61.1 (±12.7) years, 61.6% female), 87.4% reported at least one DRP, with 39.7% indicating it impacted ADL. The most frequent DRPs involved inadequate drug use, including intentionally used less (49.8%) and stopped earlier (44.6%). The most impactful DRPs involved negative experiences, including insufficient effect (69.3%) and side effect (57.6%). Opioids caused the most DRPs, averaging 1.8 per patient. Impactful DRPs were associated with female sex, knee and spine surgery, medication concerns, and younger age.</p><p><strong>Conclusion: </strong>Most patients experienced at least one DRP within 6 weeks post-discharge, with nearly half reporting an impact on ADL. Inadequate drug use and negative experiences, particularly with opioids, are the most urgent DRPs to address.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"432-438"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic drug monitoring of inhaled tobramycin in a patient with chronic kidney disease.","authors":"Rebeca Añez-Castaño, Carles Iniesta-Navalón, Miguel Almanchel-Rivadeneyra, Eva García-Villalba, Eva Oliver-Galera, Lorena Rentero-Redondo","doi":"10.1136/ejhpharm-2023-004075","DOIUrl":"10.1136/ejhpharm-2023-004075","url":null,"abstract":"<p><p>This case report investigates elevated serum concentrations of inhaled tobramycin in a patient with chronic kidney disease. The patient, a man in his early 80s with complex comorbidities, underwent tobramycin inhalation therapy for chronic respiratory infections caused by <i>Pseudomonas aeruginosa</i> Despite the strategic localised treatment approach, unexpectedly high plasma tobramycin concentrations were observed. After a dosage adjustment guided by a pharmacokinetic-pharmacodynamic model, a final inhalation dose of 300 mg of tobramycin was determined at a 24-hour interval. This case report underscores the need for rigorous monitoring of plasma tobramycin levels in patients with renal impairment undergoing inhaled tobramycin therapy, advocating for enhanced pharmacokinetic models to improve the safety and efficacy of the treatment.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"488-490"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural language processing assisted detection of inappropriate proton pump inhibitor use in adult hospitalised patients.","authors":"Yan Yan, Chao Ai, Jike Xie, Zhaoshuai Ji, Xuesi Zhou, Zhonghao Chen, Ji Wu","doi":"10.1136/ejhpharm-2024-004126","DOIUrl":"10.1136/ejhpharm-2024-004126","url":null,"abstract":"<p><strong>Objectives: </strong>To establish a clinical application monitoring system for proton pump inhibitors (PPI-MS) and to enhance the detection and intervention of inappropriate PPI use in adult hospitalised patients.</p><p><strong>Methods: </strong>Natural language processing technology was applied to indication recognition of therapeutic PPI applications and the assessment of admission record recognition for preventive PPI applications. Symptom judgement was based on the tense-negation model and regular expressions. Evidence-based rules for clinical PPI application were embedded for the construction of PPI-MS. A total of 9421 patient records using PPI from July 2022 to July 2023 were analysed to validate the performance of the system and to identify common issues related to inappropriate clinical PPI use.</p><p><strong>Results: </strong>Out of 9421 hospitalised patients detected using PPI, 4736 (50.27%) were used for prophylaxis and the rest for therapeutic use. Among the prophylactic medications, 2274 patients (48.02%) were identified as receiving inappropriate prophylactic PPI. The main reasons were inappropriate prophylaxis without indication. Additionally, 258 cases of inappropriate therapeutic PPI use were identified, mainly involving the use of esomeprazole for peptic ulcers and Zollinger-Ellison syndrome. The efficiency of the PPI rational medication monitoring system, when coupled with human involvement, was 32 times that of manual monitoring. Among cases of inappropriate prophylactic PPI use, 45.29% were due to lack of indications, 28.34% involved inappropriate administration routes, 15.74% were related to inappropriate dosing frequencies and 10.62% were attributed to inappropriate drug selection. There were 933 cases related to the use of antiplatelet and anticoagulant drugs and 708 cases related to the use of non-steroidal anti-inflammatory drugs. The overall accuracy of the PPI-MS system was 88.69%, with a recall rate of 99.33%, and the F1 score was 93.71%.</p><p><strong>Conclusions: </strong>Establishing a PPI medication monitoring system through natural language processing technology, while ensuring accuracy and recall rates, improves evaluation efficiency and homogeneity. This provides a new solution for timely detection of issues relating to clinical PPI usage.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"427-431"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving patient outcomes during cancer drug shortages: the role of patient education.","authors":"Nabin Pathak, Rajeev Shrestha, Sunil Shrestha","doi":"10.1136/ejhpharm-2025-004548","DOIUrl":"10.1136/ejhpharm-2025-004548","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"397-398"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of hospital clinical pharmacy services in Finland in the period 2017-2022: the third nationwide follow-up survey.","authors":"Lotta Linnea Schepel, Eva Kunnola, Marja Airaksinen, Kirsi Aronpuro, Kirsi Kvarnström","doi":"10.1136/ejhpharm-2024-004312","DOIUrl":"10.1136/ejhpharm-2024-004312","url":null,"abstract":"<p><strong>Background and objectives: </strong>Pharmacists' involvement in patient care became more common in Finnish hospitals during the period of 2011-2016. The first national survey was conducted in 2011 and repeated using the same method in 2016. This development was in accordance with patient safety policy initiatives and European hospital pharmacy statements. This study aimed to conduct the third national follow-up survey on hospital clinical pharmacy services in Finland in 2022 and compare the results with those in 2016.</p><p><strong>Methods: </strong>The study was conducted in 2022 as a national online survey targeting hospital pharmacies (n=22) and smaller-scale, independently operating medicine dispensaries (n=23). Descriptive statistics and qualitative content analysis were used for the data analysis.</p><p><strong>Results: </strong>The response rate was 64% (n=29/45), accounting for 19/22 hospital pharmacies and 10/23 medicine dispensaries. Clinical pharmacy services were provided in 83% (n=24/29) of the responding units. The clinical pharmacy staff increased between 2017 and 2022 and services became more common, particularly at admission units (eg, emergency departments) and outpatient clinics. In some units (25%, n=6/24), services were also available in the evenings and in one unit during weekends. Similar to 2016, system-based medication safety risk management was also highlighted in this survey, and the first medication safety officer positions (n=8/24) were created. The most increased tasks were medication reviews and medication safety audits, while in 2016 the most increased task was medication reconciliation. Pharmacist participation in patient discharge had decreased. Despite the increasing prevalence of automation technology and pharmacy assistants, logistical tasks decreased only slightly.</p><p><strong>Conclusions: </strong>Finnish hospital clinical pharmacy services have continued to expand in accordance with national and international guidelines, and have become increasingly concentrated on medication safety risk management. They currently engage in admission and outpatient units, but effort should also be put into discharge.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"413-420"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescribe less, ask more: the patient-centred pharmacology we need.","authors":"Andrej Belančić, Almir Fajkić, Dinko Vitezić","doi":"10.1136/ejhpharm-2025-004697","DOIUrl":"10.1136/ejhpharm-2025-004697","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}